“Preclinical Assessment of Ulixertinib, a Novel ERK1 2 Inhibitor”. ADMET and DMPK 5, no. 4 (December 23, 2017): 212–223. Accessed June 2, 2026. https://pub.iapchem.org/ojs/index.php/admet/article/view/437.